|
|
|
|
|
11.06.25 - 07:00
|
Research: Citi Trims Zai Lab TP to US$66, Rating Buy (AAStocks)
|
|
|
Citi Research issued a research report trimming its target price for ZAI LAB (09688.HK)(ZLAB.US's US stock from US$71 to US$66, and correspondingly adjusting its EPS estimations, due to the adoption of ZAI LAB's end-2024 share count instead of the prior 2024 weighted average share count. Citi Research rated ZAI LAB's......
|
|
|
11.06.25 - 06:15
|
Research: BofAS Elevates TPs for ZAI LAB/ TIGERMED to HKD29.61/ HKD40.1 (AAStocks)
|
|
|
BofA Securities has released a report on Chinese pharma stocks, among them ZAI LAB (09688.HK) (ZLAB.US) announced last Monday (2nd) updated data from its Phase 1a/1b clinical trial of ZL-1310 for patients with extensive-stage small cell lung cancer.In second-line treatment, the unconfirmed objective response rate across all dose......
|
|
|
06.06.25 - 10:30
|
Research: BofAS Raises ZAI LAB's TP to HKD29.61; Rating Reiterated Neutral (AAStocks)
|
|
|
ZAI LAB (09688.HK) (ZLAB.US) recently announced positive data regarding ZL-1310, according to a report from BofA Securities. With the Fast Track Designation granted by the US FDA, the group plans to initiate a Phase 3 pivotal study for second-line small cell lung cancer (2L SCLC) in 2H25.Based on the above clinical progress, Bof......
|
|
|
|
|
20.05.25 - 12:00
|
FDA grants fast track status to Zai Lab’s lung cancer treatment (PBR)
|
|
|
This ADC, which is currently under assessment in a global Phase Ia/IIb trial, has secured orphan drug designation from the agency for SCLC. According to the company, SCLC
The post FDA grants fast track status to Zai Lab's lung cancer treatment appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.05.25 - 12:03
|
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire)
|
|
|
– Total revenues grew 22% y-o-y to $106.5 million for the first quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million
– Operating loss improved significantly, declining 20% year-over-year to $56.3 million for the first quarter of 2025, and 25% to $37.1 million on an adjusted basis1; on track to achieve profitability1 in the fourth quarter of 2025
– ZL-1310 (DLL3 ADC) is advancing rapidly, with upcoming ASCO 2025 data presentation in ES-SCLC; initiation of registrational study in ES-SCLC expected in the second half of 2025
– AACR 2025 presentations of ZL-6201 (LRRC15 ADC) and ZL-1222 (PD-1/IL-12) underscore the promising potential of Zai Lab's internally developed next-generation oncology therapies
– Strong balance sheet with a cash position2 of $857.3 million as of March 31, 2025, compared to $879.7 million as of December 31, 2024
Conference call and webcast today, May 8, 2025, at 8:00 a.m. ET (8:00 p.m. HKT)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Z...
|
|
|
|
|
23.04.25 - 16:57
|
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting (Business Wire)
|
|
|
- Zai Lab will highlight potential of ZL-1310 as a promising, best-in-class Delta-like ligand (DLL3-targeted) ADC for patients with extensive-stage small cell lung cancer (ES-SCLC)
- Investor conference call and webcast to discuss data and clinical trial plans on June 2, 2025, at 7:00 a.m. CT / 8:00 a.m. ET / 8:00 p.m. HKT
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating ZL-1310, the Company's potential first-in-class and best-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), will be presented during a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. The updated results will include additional patients and follow-up from the ongoing trial of ZL-1310 in patients with previously trea...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
